Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.20.1
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Expenses        
Research and development $ 898,720 $ 735,844 $ 2,332,388 $ 2,702,213
General and administrative 1,077,642 935,530 3,045,017 2,796,884
Operating expenses 1,976,362 1,671,374 5,377,405 5,499,097
Other (income) loss        
Change in fair value of derivative liability 189 (852)
Foreign exchange (gain) loss (2,416) 5,819 (536) 16,754
Interest income (16,964) (13,397) (73,965) (49,513)
Other loss (income) (19,380) (7,389) (74,501) (33,611)
Net loss for the period 1,956,982 1,663,985 5,302,904 5,465,486
Computation of basic loss per share        
Net loss for the period 1,956,982 1,663,985 5,302,904 5,465,486
Series B Preferred stock dividend 1,473 23,202 6,071 75,477
Net loss for the period attributable to common stockholders $ 1,958,455 $ 1,687,187 $ 5,308,975 $ 5,540,963
Basic and fully diluted loss per share $ 0.17 $ 0.67 $ 0.52 $ 2.27
Basic and fully diluted number of shares 11,417,456 2,518,452 10,116,541 2,444,065